RIM
AVBP icon

Rakuten Investment Management’s ArriVent BioPharma AVBP Stock Holding History

Rakuten Investment Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$33.9K Hold
1,474
– – ﹤0.01% 518
2024
Q2 		$25.6K Buy
+1,474
New +$26.3K ﹤0.01% 527

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rakuten Investment Management's AVBP Position: Q3 2024 in Review

Rakuten Investment Management held its ArriVent BioPharma (AVBP) position steady in Q3 2024 at 1,474 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

Rakuten Investment Management first reported a position in AVBP in Q2 2024 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold AVBP as of Q3 2024.

  • Rakuten Investment Management held 1,474 shares of ArriVent BioPharma worth $33.9K as of Q3 2024.
  • Rakuten Investment Management left its ArriVent BioPharma share count unchanged in Q3 2024.
  • ArriVent BioPharma made up ﹤0.01% of Rakuten Investment Management's portfolio in Q3 2024, its #518 holding.
  • Rakuten Investment Management first reported a position in ArriVent BioPharma in Q2 2024 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2024.

Based on Rakuten Investment Management's 13F filing for Q3 2024, filed 15 May 2025.